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The tumour suppressor ARF (alternative reading frame) is en-
coded by the INK4a (inhibitor of cyclin-dependent kinase 4)/ARF
locus, which is frequently altered in human tumours. ARF binds
MDM2 (murine double minute 2) and releases p53 from inhibi-
tion by MDM2, resulting in stabilization, accumulation and activ-
ation of p53. Recently, ARF has been found to associate with
other proteins, but, to date, little is known about ARF-associated
proteins that are implicated in post-translational regulation of
ARF activity. Using a yeast two-hybrid screen, we have identified
a novel protein, LZAP (LXXLL/leucine-zipper-containing ARF-
binding protein), that interacts with endogenous ARF in mam-
malian cells. In the present study, we show that LZAP reversed the
ability of ARF to inhibit HDM2’s ubiquitin ligase activity towards
p53, but simultaneously co-operated with ARF, maintaining p53
stability and increasing p53 transcriptional activity. Expression of
LZAP, in addition to ARF, increased the percentage of cells in
the G1 phase of the cell cycle. Expression of LZAP also caused
activation of p53 and a p53-dependent G1 cell-cycle arrest in the
absence of ARF. Taken together, our data suggest that LZAP can
regulate ARF biochemical and biological activity. Additionally,
LZAP has p53-dependent cell-cycle effects that are independent
of ARF.
Key words: alternative reading frame protein (ARF), C53,
LXXLL/leucine-zipper-containing ARF-binding protein (LZAP),
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INTRODUCTION
The tumour suppressor ARF (alternative reading frame) is a
product of the INK4a [inhibitor of CDK (cyclin-dependent kinase)
4]/ARF locus, which encodes two unrelated cell-cycle inhibitors,
p16INK4a and p14ARF (p19ARF in mice) [1]. These two proteins share
nucleotide sequences in exons 2 and 3, but are specified by distinct
first exons and are translated in different reading frames. The bio-
chemical activities of the CDK inhibitor p16INK4a are well de-
scribed. It binds cyclin-D-associated CDKs to prevent phospho-
rylation of the pRb (retinoblastoma protein), thereby maintaining
pRb in its growth-suppressive state [2]. In contrast, ARF activates
p53 through direct interaction with MDM2 (murine double minute
2) or HDM2 (human homologue of MDM2) in humans, the major
negative regulator of p53 [3–5]. Activity of p53 is repressed by
MDM2 through direct inhibition of p53 transcriptional activity
[6] and through p53 degradation following HDM2-directed ubi-
quitination [7] and nuclear export [8]. ARF has been shown to
antagonize all of these functions of MDM2 [9,10].
Acting as a sensor of hyperproliferative signals, ARF is induced
by multiple oncogenes, including Myc [11], Ras [12], E1A [13],
Abl [14] and E2F1 [15] (reviewed in [16]). Following oncogenic
stimulation, increased levels of ARF induce nuclear accumulation
and activation of p53, resulting in cell-cycle arrest and/or apop-
tosis [16]. ARF has also been reported to respond to other signals,
such as DNA damage, microtubule disruption, morphological
changes and short-lived perturbations in the cell cycle and in nuc-
leolar function [17,18]. Furthermore, it has been reported that, in
several human haemopoietic tumour cell lines that express abun-
dant amounts of ARF mRNA, ARF protein cannot be detected,
indicating that post-transcriptional regulation of ARF may play a
role in certain tumour types [19]. A recent report also suggests that
binding of Tat-binding protein 1 regulates ARF protein stability
[20]. ARF stability has been found to be regulated by proteasomal
degradation after N-terminal ubiquitination [21,22]. Although
the transcriptional regulation of ARF by oncogenes and tran-
scriptional factors has been demonstrated, little is known about
the post-transcriptional regulation of ARF activity.
Several proteins, other than MDM2, have been reported to
interact with ARF, including E2F1 [23,24], neurabin II [25],
HIF-1α (hypoxia-inducible factor 1α) [26], Pex19P [27], CARF
(collaborator of ARF) [28] and B23/nucleophosmin [29–32].
Some of these proteins alter ARF localization or ARF-dependent
activation of p53 [25,27,28]. To identify ARF-interacting proteins
that may regulate ARF activity, we screened for ARF-binding
proteins using a yeast two-hybrid system. A novel human protein
that bound ARF was identified in yeast and confirmed in mam-
malian cells. This protein is highly similar to a rat protein, C53,
which has been identified previously using a yeast two-hybrid
assay as interacting with p35, the precursor of CDK5 activator
[33]. We show here that this LZAP (LXXLL/leucine-zipper-con-
taining ARF-binding protein) directly and specifically binds to
the N-terminal region of human ARF. Our data suggest that, upon
direct binding to ARF, LZAP reverses ARF inhibition of HDM2’s
p53 ubiquitination activity. Remarkably, despite its ability to
restore HDM2 ubiquitination of p53 in the presence of ARF,
expression of LZAP did not lead to p53 degradation or decreased
p53 transcriptional activity. Additionally, ectopic expression of
LZAP resulted in a G1 cell-cycle arrest that was dependent on
p53, but independent of ARF.
Abbreviations used: ARF, alternative reading frame; CDK, cyclin-dependent kinase; DAPI, 4,6-diamidino-2-phenylindole; GAPDH, glyceraldehyde-3-
phosphate dehydrogenase; GFP, green fluorescent protein; HA, haemagglutinin; HRP, horseradish peroxidase; INK4a, inhibitor of CDK4; IPTG, isopropyl
β-D-thiogalactoside; KLH, keyhole-limpet haemocyanin; LZAP, LXXLL/leucine-zipper-containing ARF-binding protein; MDM2, murine double minute 2;
HDM2, human homologue of MDM2; MEF, mouse embryonic fibroblast; pRb, retinoblastoma protein.
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MATERIALS AND METHODS
Plasmid constructs
EST (expressed sequence tag) clone (clone ID CS0DI052YB01,
GenBank® Accession number AL573636) containing LZAP
cDNA was purchased from Invitrogen. The entire coding se-
quence of LZAP was amplified by PCR using the forward primer,
5′-CGGGGTACCCATGGAGGACCATCAGCACGTGCCC-3′,
and the reverse primer, 5′-CCGTCTAGATCACAGAGAGGTT-
CCCATCAGGTTCAC-3′. The PCR product was digested with
KpnI and XbaI and subcloned into the corresponding sites in the
pcDNA3 and pcDNA3-FLAG expression vectors. All constructs
derived from PCR products were verified by direct DNA sequen-
cing. The pGL3-p21-luc p53-responsive luciferase reporter was a
gift from Dr James J. Manfredi (Mount Sinai School of Medicine,
New York, NY, U.S.A.). The p53 mutant pCEP4-p53V143A
was kindly provided by Dr Jennifer A. Pietenpol (Vanderbilt
University, Nashville, TN, U.S.A.). The yeast two-hybrid
plasmid containing LZAP cDNA, pACT2-LZAP, was obtained
from screening the human brain cDNA library using ARF as
bait.
Yeast two-hybrid assay
The procedure of yeast two-hybrid has been described previously
[3]. Briefly, yeast HF7C cells were co-transformed with pACT2
and pGBT8 constructs. Yeast transformed by both constructs were
verified by growth on medium lacking leucine and tryptophan
(−LW), and interaction between two fusion proteins was
identified by yeast growth on medium lacking leucine, tryptophan
and histidine (−LWH), and confirmed using a β-galactosidase
activity assay.
Cell culture and transfection
Mammalian tumour cell lines were maintained at 37 ◦C under
5% CO2, in Dulbecco’s modified Eagle’s medium supplemented
with 10% (v/v) foetal bovine serum. All cell culture media
and supplements were purchased from Invitrogen. Cells were
plated 24 h before transfection, transfected at 30–50% confluence
for cell-cycle analysis, and at 50–70% confluence for other
experiments using FuGene6 (Roche Molecular Biochemicals)
according to the manufacturer’s instructions. The total amount
of transfected DNA in any single experiment was kept constant
by adding empty vector (pcDNA3) as necessary.
Antibodies and immunochemistry procedures
Rabbit anti-human LZAP serum, 3486, was produced in male
New Zealand white rabbits against the KLH (keyhole-limpet
haemocyanin)-conjugated synthetic peptide CDISKRYSGRPV-
NLMGTSL corresponding to amino acid residues 489–506 of
human LZAP. The first N-terminal cysteine residue was added
to facilitate covalent KLH conjugation. This anti-LZAP antibody
was affinity-purified using a Sulfolink kit (Pierce) following
the manufacturer’s instructions, which was used in immuno-
fluorescence; and also was conjugated with HRP (horseradish
peroxidase) for immunoblotting by the Vanderbilt Molecular Re-
cognition Shared Resource. Mouse monoclonal antibodies speci-
fic to FLAG tag, M2 and HRP-conjugated M2 were purchased
from Sigma; mouse anti-ARF antibody 14P02, mouse anti-Ku
antibody Ab-2 and anti-actin antibody pan Ab-5 were purchased
from Neomarker; flurochrome-conjugated secondary antibodies
were purchased from Jackson ImmunoResearch Laboratories; and
other antibodies were from Santa Cruz Biotechnology.
Procedures for immunoprecipitation and immunoblotting have
been described previously [3]. Briefly, cells cultured in 100-mm-
diameter dishes were lysed in 0.5% (v/v) Nonidet P40 lysis buffer
supplemented with protease inhibitor cocktail (Roche). Cell ly-
sates were immunoprecipitated by incubating with specific anti-
bodies followed by Protein A- or Protein G-conjugated agarose
beads (Invitrogen) at 4 ◦C. Agarose beads were then washed
three times with lysis buffer and resuspended in Laemmli
buffer (4% SDS, 0.02% Bromophenol Blue and 100 mM
Tris/HCl, pH 6.8) for gel electrophoresis followed by immuno-
blotting.
The procedure of indirect immunofluorescence was previously
described [10]. Briefly, cells growing on six-well culture dishes
were fixed in 1 ml of buffered 3% (w/v) paraformaldehyde for
10 min at room temperature (22 ◦C), permeabilized in 0.2 % (v/v)
Triton X-100 at 4 ◦C for 5 min, and blocked with 0.5% (v/v) BSA.
Target proteins were visualized by immunostaining with specific
primary antibodies for 1 h at room temperature followed by
appropriate FITC- or rhodamine-conjugated secondary antibodies
for 30 min.
Sequential immunoprecipitation
LZAP was immunoprecipitated from 250 µg of cell lysate twice
using 5 µl of rabbit anti-LZAP serum (3486), and cleared with
Protein A-conjugated agarose beads for a total of three times.
Lysate after LZAP depletion was then similarly depleted of HDM2
by using mouse anti-HDM2 antibody (SMP14). Finally, ARF
was immunoprecipitated using 3 µl of rabbit anti-ARF serum
(10437). Repeated immunoprecipitates using identical antibodies
were combined, separated by electrophoresis and immunoblotted
as described previously.
Ubiquitin ligase assays
The procedure for ubiquitin ligase activity assay was essenti-
ally the same as has been previously described [34]. For the in
vivo ubiquitin ligase assay, U2OS (human osteosarcoma) cells in a
100-mm-diameter dish were transfected with plasmids including
pSK-HA-Ub (0.5 µg), pCMV-p53 (0.5 µg), pCMV-HDM2
(0.5 µg), pCI-neo-ARF (1 µg) and pcDNA3-LZAP (2 µg). The
total amount of plasmid DNA in each transfection was adjusted
to 4.5 µg with an empty pcDNA3 vector when needed. At 2 days
after transfection, cells were treated with 25 µM proteasome in-
hibitor MG132 for 4 h. Cells were then lysed in 100 µl of SDS
lysis buffer (50 mM Tris/HCl, pH 7.5, 0.5 mM EDTA, 1%
SDS and 1 mM dithiothreitol) by boiling for 10 min and were di-
luted in 1 ml of 0.5% (v/v) Nonidet P40 buffer. p53 was immuno-
precipitated from cell lysates with 0.6 µg of goat polyclonal
anti-p53 antibody (FL393), resolved by SDS/15 % PAGE fol-
lowed by immunoblotting with mouse monoclonal anti-HA
(haemagglutinin) antibody (F7).
For in vitro ubiquitin ligase assays, U2OS cells were transfected
as in the in vivo assay excluding pSK-HA-Ub. At 2 days after
transfection, cells were lysed, and protein complexes were im-
munoprecipitated with 0.6 µg of mouse anti-HDM2 antibody
(SMP14) or 2 µl of rabbit anti-ARF serum (10437). Immuno-
precipitates immobilized on agarose beads were washed, and
30 µl of ubiquitination reaction mixture containing 10 nM
okadaic acid, 2 mM ATP, 0.75 µg of ubiquitin, 60 ng of E1 and
300 ng of E2 within the reaction buffer (50 mM Tris/HCl, pH 7.4,
5 mM MgCl2, 2 mM NaF and 0.6 mM dithiothreitol) was added.
Reaction mixtures were incubated at 37 ◦C for 1 h with gentle
shaking at 100 rev./min. The reaction then was terminated by
adding 30 µl of 2× Laemmli buffer and boiling for 5 min. p53 was
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resolved by SDS/15% PAGE and visualized by immunoblotting
with goat polyclonal anti-p53 antibody (FL393).
Luciferase reporter assay
U2OS cells cultured in six-well dishes were transfected with
500 ng of pCI-neo-ARF and/or 500 ng of pcDNA3-LZAP to-
gether with 100 ng of the pGL3-p21-luc reporter and 10 ng
of pRL-TK (Promega) as the internal control, which expresses
luciferase from Renilla reniformis under the regulation of HSV-
TK (herpes simplex virus thymidine kinase) promoter. Luciferase
activity was measured using the Dual-Luciferase® Reporter
Assay System (Promega), and light emission was quantified
using a Monolight 2010 luminometer (BD Biosciences). To con-
trol for transfection efficiency, firefly luciferase results after
normalization to Renilla luciferase are presented, but similar
effects were observed before normalization to this control.
Stability of p53
Cycloheximide-stability assay
RKO cells cultured in six-well dishes were transfected with
1 µg of total DNA constructs including 0.1 µg of pCMV-p53,
0.2 µg of pCMV-HDM2, 0.2 µg of pCI-neo-ARF and/or 0.5 µg
of pcDNA3-LZAP. At 2 days after transfection, 60 µg/ml cyclo-
heximide was added to inhibit further protein synthesis. At the
indicated time points after cycloheximide treatment, cells were
trypsinized and lysed in 1% (v/v) SDS lysis buffer. The samples
were subjected to SDS/15% PAGE and immunoblotting.
Pulse–chase assay
RKO cells in six-well plates were transfected with plasmids in-
cluding 0.1 µg of pCMV-p53, 0.4 µg of pCMV-HDM2, 0.2 µg of
pCI-neo-ARF and/or 0.5 µg of pcDNA3-LZAP. At 2 days after
transfection, cells were incubated in 1 ml of pre-warmed medium
without methionine and cysteine for 40 min and were pulse-
labelled for 4 h with 100 µCi of EasyTag EXPRESS35S pro-
tein labelling mix (PerkinElmer). After labelling, cells were
washed with pre-warmed PBS, incubated in complete medium for
various times as indicated. p53 was immunoprecipitated using
0.6 µg of goat anti-p53 antibody (FL393), separated by electro-
phoresis and visualized with a PhosphoImager (FLA-5000; Fuji-
Film). Band intensity was quantified after subtraction of back-
ground using ImageGauge software (version 4.1; FujiFilm).
Detection of ubiquitinated p53 in subcellular fractions
U2OS cells were transfected with plasmids as described in the
in vitro ubiquitin ligase assay. At 2 days after transfection, cells
were treated with 25 µM proteasome inhibitor (MG132) for 4 h,
trypsinized, resuspended and incubated on ice for 5 min in 1 ml
of cytoplasmic extraction buffer containing 33 µg/ml digitonin,
20 mM Hepes, pH 7.4, 110 mM sodium acetate, 2 mM mag-
nesium acetate and 0.5 mM EDTA. Cell nuclei were pelleted by
centrifugation at 16100 g for 10 min, and the supernatant was col-
lected as the cytoplasmic fraction. The nuclear pellet was washed
twice with 1 ml of ice-cold PBS, lysed and diluted as de-
scribed in the in vivo ubiquitin ligase assay, and designated as the
nuclear fraction. From both cytoplasmic and nuclear fractions,
p53 was immunoprecipitated with 0.6 µg of goat anti-p53 anti-
body (FL393), and immunoblotted with a mouse anti-p53 mono-
clonal antibody (DO1). Human cytoplasmic protein GAPDH
(glyceraldehyde-3-phosphate dehydrogenase) and nuclear protein
Ku were immunoblotted as markers of cytoplasmic and nuclear
fractions with rabbit anti-GAPDH antibody (FL335) and mouse
anti-Ku antibody (Ab-2) respectively.
Heterokaryon assay
Nucleocytoplasmic shuttling was detected using a heterokaryon
assay. U2OS cells cultured in p100 dishes were transfected
with plasmids as described in the ‘Ubiquitin ligase assays’
Materials and methods section. At 5 h after transfection, cells
were trypsinized, and 2 × 105 cells were seeded on a six-well
tissue culture dish together with p53−/− MEF (mouse embryonic
fibroblast) cells at a ratio of 1:1. After 16 h, mixed cells were
treated with 60 µg/ml cycloheximide for 30 min, then fused
by addition of 500 µl of pre-warmed 50 % (v/v) poly(ethylene
glycol) 1500 at 37 ◦C for 150 s. Cells then were washed with
pre-warmed PBS three times and cultured further for 1 h in
medium containing 60 µg/ml cycloheximide. Thereafter, cells
were fixed, and ectopic proteins were visualized by indirect
immunofluorescence and nuclei were stained with 5 ng/ml DAPI
(4,6-diamidino-2-phenylindole; Sigma).
Flow cytometry and clonogenic growth analysis
Cells cultured in 100-mm-diameter plates were transfected at low
density (30–50 %) with pCI-neo-ARF (1.5 µg) and/or pcDNA3-
LZAP (1.5 µg) as well as 0.3 µg of plasmid directing expression
of GFP (green fluorescent protein)–spectrin. NARF2 and NARF2-
E6 cells were treated with 1 mM IPTG (isopropyl β-D-thio-
galactoside) 24 h before fixation. At 2 days after transfection,
cells were trypsinized and fixed in 70 % ethanol, stained with
10 µg/ml propidium iodide, and the cell-cycle distribution of at
least 5000 GFP-positive cells was analysed by flow cytometry as
described previously [35].
For clonogenic growth analyses, cells were infected with con-
trol retrovirus (pHIT-puro) or retroviruses directing expression of
ARF or LZAP (pHIT-puro-ARF or pHIT-puro-LZAP). At 1 day
after infection, 1 µg/ml puromycin was added to the medium. On
day 3 after infection, aliquots of cells were lysed for SDS/15%
PAGE and immunoblotting, and equal numbers of cells were split
on to 150-mm-diameter dishes and were selected for a total of
2 weeks before counting colonies.
RESULTS
LZAP binds ARF
To identify proteins that are capable of interacting with human
ARF, we screened a human brain cDNA library in a yeast two-
hybrid system using full-length ARF as bait. ARF-interacting
clones (232) were isolated and ARF binding of a novel protein,
LZAP, was confirmed in yeast (Figure 1A). Rabbit polyclonal
anti-LZAP antibody (3486) was made against a KLH-conjugated
peptide containing the C-terminal 18 amino acids of LZAP that are
conserved between human and mouse proteins. Binding between
ARF and LZAP was confirmed in human cells, by expressing ARF
and/or LZAP in U2OS cells followed by co-immunoprecipitation
(Figure 1B). U2OS cells were chosen because they do not express
ARF, but do express low levels of LZAP. Neither anti-ARF nor
anti-LZAP antibodies precipitated the reciprocal protein in the
absence of expressed target.
Database queries to identify homologues and conserved do-
mains revealed that LZAP shared no significant amino acid homo-
logy with any known protein and had no conserved functional
domains, except a putative leucine zipper (amino acids 357–385)
and two LXXLL motifs (amino acids 114–118 and amino acids
472–476) (Figure 2). To identify endogenous expression of LZAP,
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Figure 1 LZAP binds to ARF
(A) Yeast HF7C cells were co-transformed with the indicated plasmids, and grown on medium lacking leucine and tryptophan (−LW) to verify the presence of both bait (pGBT8, Leu+) and prey
(pACT2, Trp+) plasmids. Only interactions between bait and prey proteins allow growth on medium lacking leucine, tryptophan and histidine (−LWH). N64, amino acid residues 1–64; N64, amino
acid residues 65–132. (B) U2OS cells were transfected with pCI-neo-ARF and pcDNA3-LZAP as indicated. Immunoprecipitates (IP) were prepared using a rabbit anti-ARF (α-ARF) serum (10 437) or
a rabbit anti-LZAP (α-LZAP) serum (3486), separated by SDS/15 % PAGE and immunoblotted using HRP-conjugated 3486 and mouse anti-ARF monoclonal antibodies (14P02). Molecular-mass
sizes are given in kDa. (C) U2OS cells were transfected with pCI-neo-ARF and/or pcDNA3-LZAP, and fixed cells were immunostained with mouse anti-ARF antibody (14P02) and affinity-purified rabbit
anti-LZAP antibody (3486) before visualization by indirect immunofluorescence (ARF–FITC, LZAP–Rhodamine). (D) H1299 cells were infected by control adenovirus (C) or adenovirus directing
expression of E2F1 (E) at MOI (multiplicity of infection) of 30. At 30 h after infection, cells were lysed, and ARF–LZAP complexes were detected as described in (B). E2F1 induced ARF expression
2.5-fold in this representative experiment.
eight cultured human cell lines from multiple tumour types and
tissue origins, as well as one mouse cell line, were examined by
immunoblotting. LZAP was detected in all cell lines examined,
but expression levels varied (results not shown). In these cell lines,
no obvious relationship was identified between LZAP protein
levels and known ARF expression or p53 mutation status.
ARF and LZAP co-localize and alter subcellular localization
of one another
Since endogenous LZAP was not detectable by immunofluores-
cence, subcellular localization of LZAP was determined in trans-
fected U2OS cells, which lack endogenous ARF (endogenous
LZAP is detectable by Western blotting with anti-LZAP, 3486).
Proteins were visualized by fluorescence microscopy after indirect
immunofluorescence staining (Figure 1C). ARF, when expressed
alone, was primarily nucleolar. In contrast, in the absence of ARF,
LZAP localized to both cytoplasm and nucleus, but was clearly
excluded from the nucleolus in all cells examined (Figure 1C).
Localization patterns of expressed LZAP were similar in H1299
(human large cell lung carcinoma) and Saos2 (human osteosar-
coma) cells (results not shown). ARF localization was signific-
antly altered from primarily nucleolar to both nuclear and nu-
cleolar when expressed with LZAP. Likewise, LZAP localization
was altered if ARF was co-expressed. Nucleolar LZAP, which was
never detected in cells expressing LZAP without ARF, was found
in the majority of ARF-expressing cells (88 %). Co-expression of
ARF also decreased cytoplasmic localization of LZAP (51% in
cells expressing ARF and LZAP, 100 % in cells expressing LZAP
alone; Figure 1C, and results not shown). These data suggest that
co-expression of ARF and LZAP results in alteration of ARF
and LZAP subcellular localization with resultant co-localization
of these two proteins. All results presented are derived from the
examination of at least 200 cells from at least three independent
experiments.
Oncogenic stimulation of endogenous ARF induces
ARF–LZAP interaction
Our results suggest that exogenously expressed ARF and LZAP
bind one another in both yeast and human cells and that sub-
cellular localization patterns of LZAP and ARF are altered, re-
sulting in co-localization. To determine whether endogenous ARF
and LZAP bound to one another, we analysed H1299 cells,
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Figure 2 Nucleotide and corresponding amino acid sequences of LZAP
The leucine zipper and the LXXLL motif of LZAP are indicated.
because these cells express both ARF and LZAP. An ARF–
LZAP complex was not detected in untreated H1299 cells using
either ARF- or LZAP-specific antibodies (Figure 1D, lanes 3
and 5). Lack of ARF–LZAP interaction may be based on com-
partmentalization of ARF to the nucleolus with LZAP excluded
from the nucleolus, as suggested by our localization studies (Fig-
ure 1C). To determine whether increased endogenous ARF levels
would bind to endogenous LZAP, we induced endogenous ARF
by expression of E2F1. In E2F1 stimulated H1299 cells, binding
of endogenous ARF and LZAP was detected using antibodies
specific to either ARF or LZAP (Figure 1D, lanes 4 and 6). ARF
levels were only moderately increased (2.5-fold) in response to
E2F1, and LZAP levels were not significantly altered. Induction
of the LZAP–ARF complex suggests that LZAP may play a role
in the ARF-mediated response to the oncogenic stimulus of E2F1.
LZAP binds to the N-terminal region of ARF
ARF-binding proteins described previously, including MDM2,
interact with the first 64 amino acid residues of ARF. To initially
identify the region of ARF that is important for LZAP binding,
a yeast two-hybrid assay was performed. As expected, co-
expression of HDM2 with the full-length or the N-terminal 64
amino acid residues of ARF (N64), but not the remainder of
ARF (N64), allowed HF7C yeast cells to grow on −LWH
medium (Figure 1A). Likewise, full-length and N64 ARF, but
not N64 ARF, were able to interact with LZAP (Figure 1A).
To define further the region of ARF that is critical for LZAP
binding, FLAG-tagged full-length LZAP and truncation mutants
of Myc-tagged ARF were co-expressed in U2OS cells, and then
ARF or LZAP were immunoprecipitated from total cell lysates
using either anti-FLAG or anti-Myc antibodies. Among the ARF
mutants tested, LZAP reciprocally co-precipitated ARF peptides
containing either the first 30 amino acid residues (N30) or the
remainder of ARF (N30), but not mutants lacking the N-terminal
45 (N45, amino acids 46–132) or 64 (N64, amino acids 65–
132; note that N64 has slower electrophoretic mobility than
predicted) amino acid residues (Figure 3A). The ARF mutants
N30 and N30 do not share amino acid sequence, indicating that
each contains at least one site sufficient to bind LZAP.
LZAP, ARF and HDM2 form a ternary complex
All known activities of ARF map to the exon 1β encoded
N-terminal region, which is necessary and sufficient for binding
of HDM2 [36,37]. Our data suggest that the LZAP-binding site of
ARF at least partially overlaps the HDM2-binding site, raising
two possibilities: (i) LZAP competes with HDM2 for ARF bind-
ing, and (ii) LZAP, ARF and HDM2 can exist in a ternary com-
plex. To explore these possibilities, we first expressed LZAP and
HDM2 singly or together in U2OS cells to determine whether
they bound one another directly in the absence of ARF. No
binding of HDM2 and LZAP was detected in U2OS cells that do
not express ARF (Figure 3B). To determine whether binding of
HDM2 and LZAP to ARF were mutually exclusive, LZAP, ARF
and HDM2 were expressed in U2OS cells, and protein complexes
were immunoprecipitated. As expected, ARF immunoprecipitates
contained both LZAP and HDM2 (Figure 3C, lane 2). Even though
LZAP and HDM2 binding sites of ARF at least partially overlap,
immunocomplexes precipitated by antibodies specific to either
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Figure 3 LZAP binds to the N-terminal region of ARF, and forms a ternary complex with ARF and HDM2
(A) U2OS cells were transfected with pcDNA3-FLAG-LZAP and pcDNA3-Myc3-ARF (full-length or deletion mutants, see text for details) as indicated. Protein complexes were immunoprecipitated (IP)
with anti-FLAG (α-FLAG) (M2) or anti-Myc (α-Myc) (9E10) antibodies, and proteins were detected by blotting with HRP-conjugated M2 or 9E10 antibodies. The Myc3-tagged N64–ARF revealed
an unusually slower mobility than the Myc3-tagged N45–ARF, with relevant plasmids verified by direct sequencing. (B) U2OS cells were transfected with pcDNA3-LZAP and/or pCMV-HDM2.
Immunoprecipitates (IP) were prepared by antibodies recognizing HDM2 (α-HDM2) (SMP14) or LZAP (α-LZAP) (3486) before SDS/15 % PAGE and immunoblotting with the corresponding
antibodies. (C) U2OS cells were transfected as indicated and immunoprecipitates (IP) were prepared by antibodies specifically recognizing HDM2 (α-HDM2), LZAP (α-LZAP) or ARF (α-ARF),
separated by SDS/15 % PAGE and immunoblotted with corresponding antibodies. (D) LZAP, HDM2 and ARF were sequentially depleted from 250 µg of cell lysate as described in the Materials and
methods section. Immunoprecipitates (IP), as well as the original and depleted lysates, were subjected to SDS/15 % PAGE and immunoblotting.
LZAP or HDM2 contained all three proteins (Figure 3C, lanes 3
and 4), suggesting that LZAP, ARF and HDM2 can form a ternary
complex bridged by ARF. However, these data do not rule out the
possibility that complexes of ARF singly bound to either LZAP or
HDM2 exist when all three proteins are simultaneously expressed.
To help to determine the proportion of HDM2 and ARF bound
to LZAP, we performed sequential immunoprecipitation of U2OS
cell lysate following expression of the three proteins (Figure 3D).
LZAP was depleted from the lysate by two rounds of immuno-
precipitation. Consistent with our previous observation, LZAP
immunoprecipitates contained both ARF and HDM2 (Figure 3D,
lane 2). To determine the portion of HDM2 bound to LZAP,
HDM2 was then twice immunoprecipitated from the LZAP-de-
pleted lysate. Comparison of HDM2-bound (Figure 3D, lane 2)
and -unbound (Figure 3D, lane 3) to LZAP suggests that in
these cells a significant portion of HDM2 was complexed with
LZAP and ARF. Similarly, ARF immunoprecipitation from the
HDM2- and LZAP- depleted lysate revealed that a substantial
portion of cellular ARF was bound to LZAP (Figure 3D, com-
pare lane 2 with lanes 3 and 4). Immunoblotting of the triply
depleted lysate revealed that all proteins were efficiently immuno-
precipitated with only a small amount of ARF being detectable.
LZAP reverses ARF’s abrogation of HDM2-mediated
ubiquitination of p53
ARF inhibits HDM2 ubiquitin E3 ligase activity towards p53
in vitro and is thought to do so in vivo [38]. Our data suggest that
LZAP binds ARF without disruption of the HDM2–ARF com-
plex, raising the possibility that LZAP may regulate ARF in-
hibition of HDM2-directed p53 ubiquitination. To test this hypo-
thesis, we employed both in vivo and in vitro E3 ubiquitin
ligase assays. The in vivo ubiquitin ligase assay system takes
advantage of endogenous E1 and E2. Transfection of U2OS with
combinations of plasmids as indicated plus pSK-HA-Ub was
followed by p53 immunoprecipitation and HA blotting to detect
ubiquitinated p53 (Figure 4A). Before immunoprecipitation, the
26 S proteasome was inhibited with MG132 to allow accumulation
of ubiquitinated proteins. As expected, co-expression of HDM2
and p53 produced a ubiquitinated p53 ladder, which was markedly
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Figure 4 LZAP restores HDM2 ubiquitin E3 ligase activity towards p53 in the presence of ARF
(A) U2OS cells were transfected with combinations of plasmids as indicated and, 4 h before lysis, treated with the proteasome inhibitor MG132. Lysates were immunoprecipitated with 0.6 µg of
goat anti-p53 antibody (α-p53) (FL393), and HA–ubiquitin-modified p53 was visualized using a HRP-conjugated mouse anti-HA antibody (α-HA) (HRP-F7). (B) U2OS cells were transfected as
indicated. Immunocomplexes immobilized on Protein G–beads were prepared using mouse anti-HDM2 antibody (α-HDM2) (SMP14, lanes 1–5) or anti-ARF serum (α-ARF) (10 437, lanes 6 and
7), followed by an ubiquitination reaction. Identical lysates were immunoprecipitated (IP) in lanes 3 and 6, as well as lanes 4 and 7. Top panel: ubiquitinated p53 ladders were detected using goat
anti-p53 antibody (α-p53) (FL393). Middle panel: the presence of HDM2 was confirmed by immunoblotting with SMP14. Bottom panels: for both in vivo and in vitro assays, lysates were separated
by SDS/15 % PAGE and immunoblotted with antibodies against the indicated proteins as a marker of protein expression (bottom panels). Ub, ubiquitin.
decreased by expression of ARF (Figure 4A, lanes 2 and 3).
Surprisingly, expression of LZAP in addition to p53, HDM2 and
ARF restored the ubiquitinated p53 ladder (Figure 4A, lane 4),
suggesting that LZAP could reverse ARF inhibition of HDM2-
mediated p53 ubiquitination. This is remarkable, since ARF
strongly inhibits HDM2’s E3 ubiquitin ligase activity towards
p53. In the absence of ARF, LZAP did not measurably alter p53
ubiquitination (Figure 4A, lane 5).
To confirm these results, an in vitro ubiquitination assay was
performed. U2OS cells were transfected with combinations of
plasmids as with the in vivo assay excluding HA–ubiquitin.
HDM2 immunoprecipitates served as the source of both the
E3 ubiquitin ligase and the substrate (p53). The ubiquitination
reaction was performed following addition of purified E1, E2,
ATP and ubiquitin to the immunocomplexes. As expected, HDM2
catalysed ubiquitination of p53 that was inhibited by ARF
(Figure 4B, lanes 2 and 3). In the absence of ARF, HDM2
ubiquitin ligase activity towards p53 persisted in the presence
of LZAP (Figure 4B, lane 5). Confirming the results of the in vivo
ubiquitination assay, LZAP partially restored HDM2-directed p53
ubiquitination in the presence of ARF (Figure 4B, lane 4).
Despite our data suggesting that LZAP can bind to ARF
without disrupting the ARF–HDM2 binary complex (Figures 3C
and 3D), LZAP antagonism of ARF inhibition of HDM2 could
occur through disrupting a portion of the ARF-HDM2 complexes,
thus allowing free HDM2 to ubiquitinate p53. Since these ubi-
quitination assays measure enzymatic activity, even a small
amount of active HDM2 could result in substantial p53 ubiquitin-
ation. Alternatively, LZAP may reverse ARF inhibition of HDM2
within an LZAP–ARF–HDM2 ternary complex. To elucidate
further the mechanism by which LZAP abrogates ARF inhibition
of HDM2, we repeated the in vitro ubiquitin ligase assay; however,
instead of precipitating ubiquitin ligase complexes using anti-
HDM2 antibody, we assessed the p53 ubiquitination capacity
of HDM2 contained in anti-ARF immunoprecipitates. If LZAP
inhibited ARF activity towards HDM2 through dissociation of a
portion of ARF–HDM2 complexes, then, in the presence of LZAP,
ARF immunoprecipitates should contain less HDM2 and have
less p53 ubiquitin ligase activity. Notably, the immunoprecipitates
prepared using anti-ARF antibody contained higher ubiquitin E3
ligase activity in the presence of LZAP (Figure 4B, lanes 6 and 7)
despite having less or equivalent levels of HDM2 in the complex
(Figure 4B, lanes 6 and 7, lower panel).
Although we have not ruled out the possibility that LZAP may
recruit another p53-specific E3 ligase to the complex therefore
negating the need for active HDM2, the most straightforward in-
terpretation of the data including immunoprecipitation of HDM2
directly (Figure 4B, lanes 1–5) and of ARF-associated
HDM2 (Figure 4B, lanes 6 and 7) is that the increased ubiquitin
ligase activity seen in lanes 4 and 5 of Figure 4B is attributable
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Figure 5 LZAP increases p53 transcriptional activity and does not destabilize p53
(A) U2OS cells were transfected with the indicated plasmids in addition to 100 ng of pGL3-p21-luc (firefly luciferase) and 10 ng of pRL-TK (Renilla luciferase). Renilla luciferase activity was used as
the internal control. Normalized firefly luciferase activity of cells transfected with vector only was assigned as 1. Results are means +− S.E.M. for three independent experiments with three data points
within each experiment. (B, C) RKO cells were transfected as indicated. Total cell lysates were prepared at 0, 1, 2, 3 and 5 h after cycloheximide treatment. Actin was blotted as the loading control.
After cycloheximide treatment and immunoblotting, the amount of p53 protein at each time point was quantified (ImageQuant software version 5.0; Amersham Biosciences) and normalized based on
actin expression. p53 levels at zero time was designated 1. Results in (C) are means +− S.E.M. for three independent experiments. (D) RKO cells were transfected with the indicated plasmids and, after
2 days, were labelled with [35S]methionine/[35S]cysteine, followed by chase with unlabelled medium for the indicated times. p53 was immunoprecipitated from lysate and separated by SDS/15 %
PAGE. Bands corresponding to p53 were imaged and quantified using a PhosphoImager. Results are p53 band intensities after subtraction of background.
to HDM2 that is in a complex with ARF and LZAP. Taken
together, the ubiquitin ligase assays and the binding assays suggest
that LZAP probably restores HDM2 ubiquitin E3 ligase activity
towards p53 in the presence of ARF through formation of an
LZAP–ARF–HDM2 ternary complex.
LZAP increases p53 transcriptional activity and does not
destabilize p53
To decrease p53 protein levels and activity during normal cell
growth, ubiquitinated p53 is targeted for proteasome-mediated
degradation. In a cell line harbouring a temperature-sensitive
mutant E1, the ubiquitin-activating enzyme, it was demonstrated
that p53 degradation is largely ubiquitin-dependent [39]. How-
ever, recent evidence suggests that p53 ubiquitination alone is not
sufficient to drive degradation [40]. Given our data that LZAP
restores p53 ubiquitination in the presence of HDM2 and ARF,
we wished to determine whether LZAP altered p53 transcriptional
activity and stability. The transcriptional activity of p53 was deter-
mined using a Dual-Luciferase® Reporter Assay System with
a p53-responsive firefly luciferase reporter (pGL3-p21-luc).
Ectopic expression of ARF increased transcriptional activity of
endogenous p53 (9.5-fold; Figure 5A). Surprisingly, expression
of LZAP in addition to ARF resulted in a further increase in
transcription of the p53-responsive reporter (22-fold; Figure 5A).
In the absence of ARF, LZAP also increased p53 transcriptional
activity (5-fold; Figure 5A). A similar pattern of p53-responsive
luciferase reporter activation following expression of ARF and
LZAP was observed in RKO cells (results not shown), which ex-
press p53 and HDM2, but lack ARF expression [41].
Our data suggest that expression of LZAP allowed p53 ubi-
quitination by HDM2 in the presence of ARF, yet increased p53
transcriptional activity. Ubiquitination of p53 need not inhibit
transcriptional activity; however, ubiquitination-associated pro-
tein degradation is a major regulator of p53 activity. These seem-
ingly conflicting data may be explained if LZAP in the presence of
HDM2 and ARF: (i) represses degradation of ubiquitinated p53,
(ii) increases p53 de novo synthesis, or (iii) increases ubiquitin-
ated p53 transcriptional activity to compensate for increased de-
gradation associated with ubiquitination of p53. To begin distin-
guishing between these possibilities, we determined p53 stability
in the presence of HDM2, ARF and LZAP in RKO cells using
cycloheximide to block protein synthesis (Figures 5B and 5C).
At 2 days after transfection, protein synthesis was inhibited, and
p53 protein levels were measured by immunoblotting and quanti-
fication of band intensity at the indicated time points (Figure 5C).
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Figure 6 LZAP increases p21 protein levels and inhibits cell proliferation
(A) U2OS cells were transfected with the indicated plasmids and lysed 2 days after transfection. Protein levels were determined from cell lysates by immunoblotting with GAPDH serving as a loading
control. (B, C) Cells were transfected with the indicated DNA constructs in addition to a plasmid directing expression of GFP–spectrin. ARF expression was induced in NARF2 and NARF2-E6 cells
by treatment with 1 mM IPTG. Cell-cycle distribution of GFP-positive cells was determined by flow cytometry on a FACSCalibur (BD Bioscience) and analysed using ModFit 2.0 (Verity Software
House). Results are means +− S.E.M. for at least three independent experiments. (D) Cells were infected with retroviruses as indicated, then selected for 2 weeks before analyses of colony formation.
Expression of LZAP and ARF was confirmed in infected cells after 2 days of selection by SDS/15 % PAGE and immunoblotting. Results are means +− S.E.M. for three experiments.
As expected, ARF increased p53 stability in the presence of ex-
pressed HDM2. Notably, p53 stability following expression of
LZAP in addition to HDM2 and ARF was not decreased rela-
tive to p53 stability following expression of ARF and HDM2
(Figure 5C). Similar results were observed in HeLa cells (results
not shown). Also, LZAP in the absence of ARF did not result
in destabilization of p53 (Figure 5C, p53/HDM2/LZAP). To rule
out indirect effects of cycloheximide on p53 stability, a 35S pulse–
chase experiment was performed in RKO cells (Figure 5D). Con-
sistent with our cycloheximide data, p53 was not destabilized
following expression of LZAP, ARF and HDM2 when compared
with expression of ARF and HDM2. These data indicate that
LZAP expression, despite increasing p53 ubiquitination in the
presence of ARF and HDM2, does not result in destabilization
of p53.
LZAP increases steady-state p53 levels and inhibits
cellular proliferation
Since our data suggest that LZAP induces p53 transcriptional
activity in U2OS cells, we wished to determine whether LZAP
expression had biological consequences. A major downstream
effector and transcriptional target of p53 is the CDK inhibitor p21.
We determined p53 and p21 steady-state levels after transfection
of U2OS cells with ARF sequences, LZAP sequences or the
combination (Figure 6A). Expression of LZAP increased p21
levels less than 2-fold. Expression of ARF increased p21 levels
3.5-fold, and expression of LZAP and ARF resulted in the
largest increase of p21 (3.9-fold). Increased p21 levels correlated
with increased p53 levels following expression of LZAP or
ARF. These results are in agreement with our luciferase reporter
assays using a p21 promoter sequence (Figure 5A). To determine
whether the increased p21 levels were associated with cell-cycle
arrest, asynchronous U2OS cells were transfected with plasmids
directing expression of ARF and/or LZAP as well as GFP–
spectrin as a marker of transfected cells. After 2 days, the cell-
cycle distribution of GFP-positive U2OS cells was analysed by
flow cytometry (Figure 6C). On average, expression of ARF
or LZAP singly, or the combination of ARF and LZAP, led
to significant increases in the percentage of G1 cells (one-way
ANOVA: P < 0.0001, for the four groups) (Figure 6B). Combined
LZAP and ARF expression resulted in G1 proliferative arrest that
was significantly greater than cells expressing ARF (P < 0.05) or
LZAP (P < 0.0001) singly.
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Since LZAP increased p53 transcriptional activity and G1 cell-
cycle arrest in the absence of ARF (Figures 5A and 6B), we
used isogenic U2OS-derived cell lines (NARF2 and NARF2-E6)
to determine whether the ARF-independent cell-cycle arrest ob-
served with LZAP expression was p53-dependent. Both NARF2
and NARF2-E6 cells inducibly express ARF, but p53 activity is
blocked in NARF2-E6 cells by constitutive expression of human
papillomavirus oncoprotein E6 [5]. As observed with U2OS
cells, expression of LZAP with or without IPTG-induced ARF
in NARF2 cells resulted in a significant increase of G1 cell popu-
lation (one-way ANOVA: P = 0.0002) (Figure 6B). In contrast,
expression of LZAP and induction of ARF, either alone or in
combination, did not cause a G1 arrest in NARF2-E6 cells (one-
way ANOVA: P = 0.3226) (Figure 6B). The G1 cell-cycle arrest
caused by ectopic expression of LZAP in U2OS cells was also
abolished by co-expression of p53V143A, a dominant-negative p53
mutant that is deficient in DNA binding (results not shown).
Consistent with these observations, ectopic expression of ARF,
LZAP or the combination of ARF and LZAP did not cause a cell-
cycle arrest in two p53-deficient cell lines, H1299 and Saos2
cells (results not shown). Likewise, colony-formation assays
were performed in p53-negative H1299 cells and p53-positive
U2OS and HT1080 following infection with retroviruses directing
expression of ARF or LZAP (Figure 6D). Expression of LZAP
and ARF inhibited colony formation in both p53-positive cell
lines, but not in the p53-negative H1299 cells.
LZAP increases nuclear ubiquitinated p53
When expressed in the presence of HDM2 and ARF, LZAP
restored p53 ubiquitination (Figure 4), but did not result in p53
degradation or decreased p53 transcriptional activity (Figure 5).
To confirm these data and to explore potential mechanisms,
we inhibited the 26 S proteasome and determined levels of
ubiquitinated p53 in nuclear and cytoplasmic fractions of U2OS
cells following expression of p53, HDM2, ARF and LZAP
(Figure 7A). p53 was immunoprecipitated from nuclear and
cytoplasmic lysates, and ubiquitinated p53 ladders were identified
by p53 immunoblotting. As expected, ubiquitinated p53 was
detected in cytoplasmic fractions of cells expressing HDM2 and
p53 (Figure 7A, lane 2). Also, cytoplasmic ubiquitinated p53 was
decreased in cells expressing ARF in addition to HDM2 and
p53 regardless of the presence of LZAP (Figure 7A, lanes 3
and 4). Ubiquitinated p53 species were more abundant in the
nuclear fractions (Figure 7A, lanes 6–10). As expected, HDM2
expression increased ubiquitinated p53 species, and co-expression
of ARF decreased accumulation of nuclear ubiquitinated p53
(Figure 7A, lanes 6–8). In the presence of ARF and HDM2,
LZAP restored nuclear ubiquitinated p53 species (Figure 7A,
lane 9). Expression of LZAP in the absence of ARF did not alter
ubiquitination patterns of p53 in either cytoplasmic or nuclear
fractions. Human Ku and GAPDH immunoblotting confirmed
nuclear and cytoplasmic fractionation. HDM2, LZAP and ARF
expression was confirmed by immunoblotting (results not shown).
Our data suggest that, in the presence of ARF and HDM2, LZAP
restores HDM2-mediated p53 ubiquitination, but under these
circumstances, ubiquitinated p53 is not destabilized and is pri-
marily localized to the nucleus. To determine whether LZAP alters
p53 nucleocytoplasmic shuttling, we performed a heterokaryon
assay in which human U2OS cells expressing p53, HDM2, ARF
and LZAP were fused with p53−/− MEFs (Figure 7B). If p53
shuttles from the human nucleus to the fused cellular cytoplasm,
random re-import of p53 into either the mouse or human nucleus
is possible. Shuttling is indicated by the presence of p53 in the
p53−/− mouse cell nucleus. Localization of p53 was determined by
indirect immunofluorescence, and mouse cell nuclei were identi-
fied by DAPI staining. As expected, p53 shuttling was observed in
cells that expressed p53 and HDM2, as indicated by the presence
of p53 in mouse nuclei (Figure 7B, p53/HDM2 column). p53
shuttling was not altered by the expression of LZAP in the
absence of ARF (Figure 7B, p53/HDM2/LZAP column). As ex-
pected, expression of ARF in addition to p53 and HDM2
inhibited p53 shuttling (Figure 7B, p53/HDM2/ARF column).
Likewise, no p53 shuttling was observed following expression
of LZAP in the presence of ARF and HDM2 (Figure 7B,
p53/HDM2/ARF/LZAP column). For all shuttling experiments,
more than 30 heterokaryons were observed, and p53 shuttling was
consistent in all scored cells.
These findings are consistent with our ubiquitination assays, as
well as p53 stability and transcriptional activity data (Figures 4
and 5), and together suggest that LZAP in the presence of ARF
and HDM2 allows for nuclear localization of ubiquitinated p53
forms. Taken together, our data suggest that ubiquitinated p53 in
the presence of ARF and LZAP does not shuttle, and is localized
to the nucleus where it is transcriptionally active.
DISCUSSION
p53 activity within the cell is tightly controlled, primarily
through regulation of p53 stability. In embryonic development,
stabilization of p53 as a result of homozygous loss of MDM2
results in embryonic lethality that can be rescued by simultaneous
loss of p53, suggesting that, at least in development, MDM2/
HDM2 is the major controller of p53 [42,43]. Because of its cen-
tral role in regulation of p53, HDM2 activity is also regulated
at multiple levels. ARF binds HDM2 and inhibits its E3
ubiquitin ligase activity towards p53, while simultaneously re-
versing HDM2’s inhibition of p53 transactivation [36]. ARF ex-
pression is induced by multiple different oncogenic stimuli result-
ing in p53-dependent cell-cycle arrest and/or apoptosis [16,44].
In this capacity, ARF seems to direct a major cellular defence,
protecting the organism from cells with excessive proliferative
signalling and, as such, many human tumour types frequently lack
expression of ARF. In this study, we identified and characterized
a novel protein, LZAP, which regulates ARF activity towards
HDM2. Our data suggest that LZAP also has ARF-independent
cell-cycle regulatory activities that depend on p53.
At least two mechanistic models of ARF regulation of HDM2
exist: (i) ARF dissociates HDM2 from p53 and sequesters
MDM2 in the nucleolus [9,45], and (ii) ARF binds to HDM2–p53
in the nucleus, forms a ternary complex and within the complex
inhibits HDM2’s ubiquitination and transcriptional inhibition of
p53 [10,36]. The nucleolar sequestration model suggests that ARF
must dissociate p53 from MDM2 and that sequestration of HDM2
in the nucleolus is vital for ARF activity. Direct experimental
evidence has shown that ARF mutants excluded from nucleoli
are capable of stabilizing and activating p53 equally as well as
wild-type ARF [37], and recent data suggest that nucleolar ARF
may be inactive towards p53 and that B23/nucleophosmin may
play a role in antagonizing ARF activity by sequestering ARF in
the nucleolus [32]. The role of nucleolar ARF in the regulation of
p53 remains controversial.
Our data favours the ternary p53–HDM2–ARF complex model.
In addition to the binding data (Figure 3) which suggest that
HDM2, ARF and LZAP are capable of forming a complex, ubi-
quitination and p53 stability data support the existence of quater-
nary p53–HDM2–ARF–LZAP complexes. ARF complexes preci-
pitated from in vitro ubiquitination assays (Figure 4B, lanes 6
and 7) not only contained p53 protein, but also contained p53
ubiquitination activity that was increased in the presence of
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Figure 7 p53 is ubiquitinated and retained in nuclei in the presence of HDM2, ARF and LZAP
(A) U2OS cells were transfected with the indicated plasmids. At 2 days after transfection, the proteasome was inhibited, and cytoplasmic and nuclear fractions of cell lysates were prepared. p53
was immunoprecipitated (IP) using a goat anti-(full-length p53) antibody (α-p53) (FL393), and ubiquitinated p53 ladders were detected by immunoblotting with mouse anti-p53 antibody (DO1).
Human cytoplasmic protein GAPDH and nuclear protein Ku were blotted as the markers of cytoplasmic and nuclear fractions respectively. (B) Heterokaryon assay was performed by transfection
of U2OS cells with the indicated plasmids before fusion with p53−/− MEFs. Nucleocytoplasmic shuttling of p53 was determined by indirect immunofluorescence. LZAP and ARF expression
was verified by indirect immunofluorescence. Representative fused cells are shown from more than 30 examined for each experiment. Mouse nuclei were distinguished by punctate staining with
DAPI.
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LZAP. Had LZAP disrupted the p53–HDM2–ARF complex by
competing for ARF, then ARF immunoprecipitates would contain
LZAP, but no p53 and no HDM2 ubiquitin ligase activity to-
wards p53. Likewise, if LZAP competed with HDM2 for ARF,
the addition of LZAP to p53–HDM2–ARF complexes should
decrease p53 stability and increase nuclear cytoplasmic shuttling.
Since we observed no decrease in p53 stability and no nuclear
cytoplasmic shuttling of p53 following the addition of LZAP in the
presence of HDM2 and ARF (Figures 5 and 7), our data suggest
that LZAP alters ARF activity within a complex containing p53–
HDM2–ARF.
ARF inhibits HDM2-mediated p53 degradation while simul-
taneously inhibiting HDM2 ubiquitination of p53; however, p53
ubiquitination and degradation activities of HDM2 can be sepa-
rated, since mutants of MDM2 have been described that can ubi-
quitinate p53, but that cannot direct p53 degradation [46]. Also,
ARF inhibition of HDM2 ubiquitin ligase activity is not absolute
since HDM2 bound to ARF still has ligase activity, just not to-
wards p53 [47]. The fate of ubiquitinated p53, and the sequence
and subcellular localization of p53 ubiquitination has been the
subject of intense investigation and debate. Some studies suggest
that p53 degradation requires nuclear export [8,48,49]. Other
studies suggest that nuclear ubiquitinated p53 can be degraded
without export [50,51]. Our data suggest that LZAP reverses ARF
inhibition of HDM2 and allows p53 ubiquitination in the nucleus.
Although ubiquitinated p53 exists in the presence of HDM2,
ARF and LZAP, it is not exported from the nucleus (Figure 7).
Assuming that both nuclear and cytoplasmic degradation of ubi-
quitinated p53 contribute to its degradation, inhibition of nuclear
export may partially explain LZAP restoration of HDM2-directed
p53 ubiquitination without subsequent destabilization. Our data
does not exclude the possibilities that LZAP in the presence
of ARF may restore HDM2 mono-ubiquitination, but not poly-
ubiquitination of p53, that LZAP may allow only low levels of
p53 ubiquitination that would require nuclear export for de-
gradation, or that LZAP may inhibit targeting of ubiquitinated p53
to nuclear proteasomes as additional mechanisms of stabilizing
ubiquitinated p53.
Our data suggest that LZAP allows nuclear accumulation of ubi-
quitinated and transcriptionally active p53 in the presence of
ARF and HDM2. Given that p53 is tightly regulated by HDM2
and ARF, why would additional regulation of ARF be necessary?
Mechanisms that ensure a rapid increase in p53 activity, such as
post-translational modification, are necessary to prevent growth
of damaged cells, but perhaps as important, mechanisms to ensure
rapid inhibition of p53 activity must be in place to allow cellular
survival and division under appropriate conditions. Ubiquitinated,
but active, p53 in the nucleus may be very susceptible to rapid
nuclear export and degradation following loss or inhibition of
ARF. Although regulators that increase ARF expression are
characterized, and loss of ARF in tumour cells is very common
through deletion or transcriptional silencing of the ARF gene,
mechanisms of ARF inactivation under normal cellular growth
conditions are not well characterized.
We report identification of an ARF-binding protein that abro-
gates ARF inhibition of HDM2 ubiquitin ligase activity. Despite
increasing ubiquitination of p53 in the presence of HDM2 and
ARF, LZAP expression did not result in loss of stabilization
of p53 protein and enhanced p53 transcriptional activity further.
These characteristics, as well as induction of endogenous ARF–
LZAP interaction following E2F1 oncogene stimulation, imply
a possible role of LZAP in ARF-mediated tumorigenesis sur-
veillance. Regulators of LZAP are presently unknown, but, given
its biochemical activity, LZAP could serve as a means of pro-
longing ARF-directed p53 responses that would otherwise be
dampened by increased HDM2 expression as part of a p53-
directed negative-feedback loop. Since our data suggest that
LZAP allows ubiquitination of p53 with maintenance of p53
activity, ARF down-regulation under these circumstances may
result in a rapid decrease in p53 protein levels and p53 activity.
Our data also suggest that LZAP can activate p53 transcription
and cause a p53-dependent cell-cycle arrest in the absence of
ARF. Further studies are needed to determine the mechanism
of ARF-independent p53 activation by LZAP.
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